Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2011 Nov 17;105(12):1850–1855. doi: 10.1038/bjc.2011.493

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2011 Cancer Research UK

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

¹¹C-erlotinib accumulation in lymph nodes that were negative on ¹⁸F-FDG PET/CT in a 42-year-old patient (no. 6). (A) Left: transaxial slices of contrast-enhanced CT; middle: ¹⁸F-FDG PET/low-dose CT; right: ¹¹C-erlotinib PET/low-dose CT. CT (left figure) showed an enlarged lymph node (>10 mm) at position 7 (arrow) and non-enlarged lymph nodes (<10 mm) at positions 10R and 10L (arrows). None of these lymph nodes were visualized by ¹⁸F-FDG PET/CT (arrows, middle figure), whereas both enlarged and non-enlarged lymph nodes were visualized by ¹¹C-erlotinib PET/CT (arrows, right figure). The ratio between ¹¹C-erlotinib average radioactivity concentrations in the lymph nodes and that in surrounding lung tissue was 2. (B) Comparison of pre-treatment and 1-year post-treatment CT scans showed no significant change in the size of any of these lymph nodes.